Finanzen von Chemed Corp (CHE)CHEChemed Corp

Chemed Corporation (CHE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Short-term core , accounting for 25.5% of total sales, equivalent to $157.52M. Other significant revenue streams include Water restoration and Independent contractors. Understanding this composition is critical for investors evaluating how CHE navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Chemed Corporation maintains a gross margin of 30.37%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.22%, while the net margin is 10.06%. These profitability ratios, combined with a Return on Equity (ROE) of 27.11%, provide a clear picture of how effectively CHE converts its operational activities into shareholder value.

In the context of the broader market, CHE competes directly with industry leaders such as PACS and UHS. With a market capitalization of $6.75B, it holds a significant position in the sector. When comparing efficiency, CHE's gross margin of 30.37% stands against PACS's 15.66% and UHS's 100.00%. Such benchmarking helps identify whether Chemed Corporation is trading at a premium or discount relative to its financial performance.

Chemed has shown consistent revenue growth, with Q2 2026 revenue at $673 million, an 8.8% increase year-over-year. The gross margin is stable at around 30%, and the net margin is approximately 10%.